Results From phase III PROpel trial of Lynparza + abiraterone in first-line metastatic castration-resistant prostate cancer published in NEJM Evidence.

Results from the trial showed that Lynparza in combination with abiraterone plus prednisone significantly improved radiographic progression-free survival (rPFS) versus abiraterone plus prednisone, a standard of care, as first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) with or without homologous recombination repair (HRR) gene mutations.

As previously reported, in the Phase III PROpel trial, Lynparza in combination with abiraterone plus prednisone (n=399) reduced the risk of disease progression or death by 34% (HR=0.66 [95% CI, 0.54-0.81]; p<0.0001) versus abiraterone plus prednisone and placebo (n="397)." median rpfs was 24.8 months for lynparza plus abiraterone versus 16.6 months for abiraterone. the most common adverse events (aes) (?20%) for lynparza plus abiraterone were anemia (46%), fatigue (37%) and nausea (28%). grade ?3 aes were anemia (15%), hypertension (4%), urinary tract infection (2%), fatigue (2%), decreased appetite (1%), vomiting (1%), back pain (1%), diarrhea (1%) and nausea (0.3%). approximately 14% of patients who received lynparza in combination with abiraterone discontinued treatment due to an ae.

Lynparza is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations) who have progressed following prior treatment with enzalutamide or abiraterone and in the European Union, Japan and China for patients with BRCA-mutated mCRPC who have progressed following prior therapy that included a new hormonal agent (NHA)

See-"Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer"; N.W. Clarke and Others 10.1056/EVIDoa2200043 .NEJM Evidence.